Monopar Therapeutics Inc. SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense
Monopar Therapeutics Inc. (MNPR) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense of $877.12 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-27.
Discontinued › Notes › Valuation and Qualifying Accounts
us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense · last filed 2020-03-27
- Monopar Therapeutics Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2019 was $877.12K, a 27.15% increase from fiscal 2018.
- Monopar Therapeutics Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2018 was $689.82K, a 48.12% increase from fiscal 2017.
- Monopar Therapeutics Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2017 was $465.73K, a 1.25% increase from fiscal 2016.
- Monopar Therapeutics Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2016 was $460.00K.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 12 month |
|---|---|
| 2019-12-31 | $877.12K 10-K · filed 2020-03-27 |
| 2018-12-31 | $689.82K 10-K · filed 2020-03-27 |
| 2017-12-31 | $465.73K 10-K · filed 2019-02-26 |
| 2016-12-31 | $460.00K 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |